https://www.selleckchem.com/products/azd2014.html
The fore-mentioned β-blockers (bisoprolol, carvedilol, and metoprolol succinate) can be initiated early, even in stable and symptom-free (at rest) subjects with heart failure. β-blockers in heart failure should be commenced at small doses and then titrated upward as tolerated to achieve the desired clinical effects on heart rate and symptom control. Cardiologists should weigh the benefit-risk in subjects with heart failure and other co-existing cardiovascular problems such as atrial fibrillation and diabetes. Cardiologists should weigh
Like
Comment
Share
